HHS Secretary Xavier Becerra (Patrick Semansky/AP Images)

Five Pfiz­er drugs among first 27 now sub­ject to Medicare in­fla­tion re­bates, HHS says

The De­part­ment of Health and Hu­man Ser­vices (HHS) on Wednes­day un­veiled the first set of 27 Part B pre­scrip­tion drugs, in­clud­ing five from Pfiz­er, that will be sub­ject to Medicare in­fla­tion re­bates be­cause their prices rose faster than the rate of in­fla­tion.

Se­niors re­ceiv­ing the physi­cian-ad­min­is­tered drugs be­gin­ning in April will have low­er coin­sur­ance for these drugs (list­ed be­low) and HHS said they may see their out-of-pock­et costs for these drugs de­crease by as much as $390 per av­er­age dose.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.